Ispire Technology Inc. Q4 FY2025 Earnings Call

Hello, everyone, and welcome to Ispire Technologies Earnings Conference Call for the Fourth Quarter and Full Year for fiscal 2025. I would now like to introduce Phil Carlson, from KCSA Strategic Communications. Please go ahead, sir.

Hello, everyone, and welcome to Ispire Technologies Earnings Conference Call for the fourth quarter and fiscal year 2025 ended June 30, 2025. At this time, I'd like to inform you that this conference call is being recorded and that all participants are in a listen-only mode. Following the company's prepared remarks, we will be facilitating our question-and-answer session. Joining us today are Mr. Michael Wang, the company's Co-CEO; and Mr. Jie Yu, the company's CFO. Mr. Wang will start by reviewing the company's key fiscal fourth quarter and full year 2025 financial results and recent corporate highlights. Mr. Yu will then discuss the company's financial results in greater detail. Before I begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts in this announcement are forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the company in terms of its experience and perception of historical trends, current conditions, and expected future developments, as well as other factors that the company believes are relevant. These forward-looking statements involve known and unknown risks and uncertainties, and many factors could cause the company's actual results or performance to differ materially from those expressed or implied by the forward-looking statements. Further information regarding this and other risk factors are included in the company's filings with the SEC. The company undertakes no obligation to update forward-looking statements to reflect subsequent or current events or circumstances or to changes in its expectation, except as may be required by law. I will now turn the call over to Mr. Wang. Mr. Wang, please go ahead.

Thank you, Phil, and welcome to everyone who has joined us today. I'm pleased to be here reviewing our fiscal fourth quarter and full year 2025 results and recent corporate highlights. Fiscal year 2025 was a pivotal period for Ispire. We made important strategic decisions to position Ispire for sustainable long-term growth and executed on this transformation across several areas of the Ispire business. While our revenue declined during the fourth quarter and full year 2025, this was due to our strategic pivot away from the cannabis industry to focus more on the higher-value nicotine sector. This intentional shift reflects our disciplined approach to building a more sustainable and profitable business model. We have been selective in our cannabis operations while simultaneously investing in our nicotine manufacturing capabilities. This includes scaling up our production in Malaysia. Additionally, our investments in breakthrough technologies like IKE Tech and our G-Mesh technology are beginning to gain significant traction with interest from major tobacco companies, positioning us well for future growth as we move through the regulatory approval process. As I just mentioned, in fiscal 2025, we continued to invest strategically in the build-out of our facilities in Malaysia and have several very exciting business development opportunities that we hope to report on in the coming quarters. Our Malaysian operations are planned to have capacity for up to 80 production lines, significantly growing our manufacturing abilities from the 6 lines we are currently operating. Our focus on production in Malaysia not only diversifies our production base and reduces risks from geopolitical factors, but also positions us to capitalize on the growing global demand for precision dosing vaping. As I have discussed, on the cannabis front, we made the intentional decision to refocus on quality of customers versus quantity, given the ongoing uncertainty and the financial challenges facing all players in the cannabis industry. This approach prioritizes building sustainable, long-term partnerships over short-term volume gains. This has already translated into improvements with a cut to expenses in several areas. We reduced our net accounts receivable on a year-over-year basis by over 21% from fiscal 2024 to fiscal 2025. This is the first time in the company's history that the net accounts receivable declined year-over-year. In addition, we reduced our quarter-over-quarter gross accounts receivable by $6.9 million or 9.1% from Q3 of fiscal 2025 to Q4 of fiscal 2025. We also reduced our general and administrative expenses from $7.6 million in fiscal Q3 2025 to $6.7 million in fiscal Q4 2025. These improved metrics are a result of our focus on reducing fixed costs while further streamlining our operations. During fiscal 2025, we undertook significant cost optimization measures, reducing annual expenses by an estimated total of $10.2 million. These actions have positioned our company to become a more focused and agile organization while enhancing our path to profitability. We expect the trend of declining costs to continue in the coming quarters as we maintain our focus on larger, higher-quality customers with improved payment terms, and as we strengthen our financial stability. On the regulatory front, we continue to advance our PMTA activities for our own devices while awaiting updates on the groundbreaking component PMTA submission filed by our strategic joint venture, IKE Tech LLC. As we have previously discussed, this blockchain-based age verification technology represents a potential game changer for the industry, requiring continuous real-time authentication rather than the single point of purchase verification used by traditional systems. The FDA's review of what could be the first-ever component PMTA approval remains a critical milestone that would unlock modular deployment across hundreds of ENDS products, fundamentally transforming the regulatory landscape for nicotine delivery systems. We remain committed to our role as a regulatory leader, continuing to invest in compliance initiatives that position us at the forefront of the key evolving market. Looking ahead, our international nicotine ODM business represents a key growth opportunity that is now gaining significant momentum after a slower-than-anticipated start. This acceleration in our ODM business, combined with our expanding Malaysian manufacturing capabilities, positions us well to capitalize on growing global demand for precision rating technology. As we continue to build out our international manufacturing footprint, we expect our ODM partnerships to be a substantial contributor to our revenue growth in the coming quarters. We have also strengthened our leadership team with the appointment of Jie Yu as our new Chief Financial Officer in May. Jie brings extensive public company accounting experience and has demonstrated exceptional performance as our Vice President of Finance since June 2023, building deep knowledge of our operations and financial structures. This promotion reflects our commitment to maintaining strong financial stewardship as we navigate this period of transformation. To sum up, we delivered substantial progress across our key strategic priorities during the fourth quarter and fiscal year 2025 while maintaining financial discipline. Most importantly, our revenue decline this quarter was a result of our intentional strategic shift away from cannabis toward the higher-value nicotine sector, positioning us for stronger and more sustainable growth ahead. I will now turn the call over to our new CFO, Jie Yu to review our financial results in more detail. Jie?

Thank you, Michael, for introducing me, and thank you to everyone for joining the call today. I'm pleased to be here to review Ispire's key financial results for the fourth quarter and the fiscal year 2025. As a reminder, I will refer to fiscal year 2025 as the year ended on June 30, 2025. All comparisons are to the prior fourth fiscal quarter or year ended June 30, 2024 unless otherwise stated. Dollar revenue for the fiscal year 2025 declined from $151.9 million to $127.5 million or by $24.4 million versus fiscal year 2024. As Michael has discussed, this was due to realignment of our business toward nicotine while moving away from cannabis customers, which we believe will deliver improved accounts receivable and more sustainable long-term growth. Taking a look at revenue by geographic regions, for fiscal 2025, European revenue totaled approximately $74.5 million, an increase of $8.8 million or 13.6% compared to $65.3 million last year. For fiscal 2025, North American revenue was approximately $32.6 million compared to $63.1 million in fiscal 2024. This was predominantly due to our strategic pivot away from cannabis and being more selective with larger and quality customers such as MSOs. For fiscal 2025, revenue from Asia Pacific totaled approximately $12.3 million compared to $17.6 million last fiscal year. For fiscal 2025, revenue from other countries was $8.5 million, an increase of $2.6 million compared to $6 million in fiscal 2024. The majority of these sales are from South Africa. During fiscal 2025, gross profit declined to $22.7 million from $29.8 million for the year prior. Gross margins were 17.8% for fiscal year 2025, a decrease of 1.8% from 19.6% in fiscal 2024. As Michael has discussed, this was due to the strategic repositioning away from cannabis, which led to the revenue reduction for this period. Operating expenses over the 12 months period to June 30, 2025 were $60.5 million, up from $43.7 million for fiscal 2024. This increase was largely due to a rise in sales and marketing expenses with a ramp-up of marketing activities as well as an increase in bad debt expense for an allowance in credit losses, offset by a decrease in stock-based compensation expense due to headcount reductions in streamlining North American operations and a reduction in R&D expenses. Importantly, since Q3 2025, general and administrative expenses declined by $0.9 million, reflecting the impact of our cost-cutting initiatives that Michael discussed in detail, which we expect to continue into fiscal 2026. For fiscal 2025, net loss was $39.2 million compared to $40.8 million in fiscal 2024. Moving now to the balance sheet, at June 30, 2025, Ispire held cash of $24.4 million, a reduction of $10.7 million versus the previous year, with a working capital balance of $0.4 million. For the 12 months to June 30, 2025, net cash flow used by operating activities was $7.4 million compared to $18.3 million in the same period last year. Net cash used in investing activities for the 12 months to June 30, 2025 was $5.2 million compared to $3 million provided by investing activity in the prior comparable period. Net cash provided by financing activities for the 12 months to June 30, 2025 was $1.9 million compared to $10.1 million used in the same period last year. This concludes our review of the financial results for fiscal fourth quarter and full year 2025. I will now hand the call back over to Michael.

Thanks, Jie. In closing, I'm proud of the substantial organizational and operational transformation we achieved throughout our fiscal fourth quarter and the full year 2025. As I outlined today, we accomplished multiple critical strategic objectives this period. Further developing our Malaysian manufacturing capabilities; dramatically accelerating our international ODM business with over $18 million in pipeline revenue; strengthening our financial position through improved accounts receivable management and significant expense reductions; and advancing our regulatory initiatives, including ongoing PMTA progress. Furthermore, our successful pivot from cannabis to the higher-value global nicotine market demonstrates our strategic agility and commitment to building a more profitable and sustainable business model. Looking ahead, Ispire is uniquely positioned to capture several transformative growth opportunities. Our exclusive Malaysian manufacturing authorization provides unparalleled competitive advantages in the global nicotine market, while our breakthrough technologies like IKE Tech's age-gating system and our G-Mesh innovation have the potential to reshape industry standards for safety and performance. Combined with our expanding ODM partnerships and strategic focus on regulatory compliance, we are exceptionally well-positioned to emerge as a leader in the precision dosing vaping technology while setting new benchmarks for responsible industry practices. Thank you to our investors for their support through this pivotal transformation and to everyone who joined us today. We look forward to reporting on our continued progress and exciting developments in the coming quarters. If you have any questions, please contact us through email at [email protected]. This completes our prepared remarks, and we are now open to questions. Operator, please go ahead.

Our first question comes from the line of Pablo Zuanic with Zuanic and Associates.

Look, just the first question in terms of age-gating technology. Can you tell us about what are the key milestones to look for here over the next few months or years what's the timetable? What's the realistic target date for approval, if you have any visibility on that, please?

Thank you, Pablo. Right now, the age-gating technology is being discussed not only within the United States but on a global basis; this has become a hot topic. Many countries are looking at this technology and progress, some could be much faster than others out there. Now back to the U.S., with this technology, we filed the component PMTA back in late April. Within 4 weeks, we received the FDA's acceptance letter, which is really speedwise unprecedented. Never before did the FDA accept any applications regarding the nicotine business within 4 weeks. So, of course, we are very encouraged by that speed. This particular application is expected to be reviewed on an expedited basis. We don’t know exactly when the next step will happen, but typically, a major next step is the FDA's issuance of a letter called a deficiency letter. Generally, that's based on the FDA's evaluation of your product. If there are minor modifications or fixes that need to be made before the green light, typically the FDA issues such a deficiency letter to suggest the company or brand fix and overcome the deficiency. So, regarding the U.S. FDA’s response to Pablo, we don’t know exactly when that letter would arrive. That generally is the next step. It could be as quick as 3 months or as long as, in some cases, over a year for other nicotine-specific products. But this is a unique application, so certainly, it's the first case of the so-called component PMTA that the FDA is reviewing or has reviewed, so there is no prior experience regarding this. We trust that with youth access to e-cigarettes being such a worldwide epidemic, lawmakers and regulators will find a suitable solution for this crisis. We feel we are at the forefront of this solution offering, Pablo.

Right. On the same topic, is it realistic to expect that perhaps in other major markets outside the U.S., maybe the EU, that you could get approval for the age verification technology sooner than in the U.S. or would the U.S. probably happen first?

Pablo, of course, we are very optimistic about the project getting special attention from the FDA for the purpose of solving this crisis, and we certainly are hoping that in short order, we would receive such a letter from the FDA. That will be very encouraging to the industry and to us specifically. However, at least 2 countries could potentially get ahead of the FDA at this point. I'm not at liberty to share the names of those 2 countries, but the regulators are embracing this technology with open arms. And in several other countries, we have been working with regulators as well. We don’t have an expected timeline at this point, but 2 are moving real fast outside the U.S.

Right. And I'm sorry, 1 more on the same topic, if I may. In terms of age verification, I know you said you believe that you're at the forefront of this technology. Can you talk about your patents and intellectual property? How are you protecting this because I'm assuming there are other companies that are also working on similar technologies, but as you think you will be first. But just remind us about the protections you have from an IP perspective?

Yes. Indeed, Pablo, for every major development, we have filed the patents, especially in the United States, EU, U.K., and China, et cetera. Our IP is a key enabler in this particular solution. So we own critical patents and our IP in this space, especially in one key area: how the device communicates to the back-end data processing to ensure the mechanism, specifically for blockchain-based technology. So we strongly believe our IP defensibility is very strong. From the beginning of this project, we have been building IP as a key strategy not only in providing such a solution, but more importantly, in defending such a solution. So both on the use for blockchain site and on the unique communication with data processing, generally government approved and compliant operators and such as CLEAR. Those are unique IP for us, Pablo.

If I may, I have two more questions. The first is regarding the receivables. You mentioned a significant provision of $22 million in the fourth quarter. Was that associated with just one client in a specific region? It seems like a large provision on receivables, so any additional details would be helpful. The second question relates to the shift away from cannabis; however, the U.S. cannabis market remains a $30 billion industry, with vape accounting for about 25% of that. There is still demand for vape parts, and it seems that opportunity is present for someone. I understand the challenges in the economics, but I'm trying to grasp the reasoning behind the pivot away from cannabis. If you could address these two questions, that would be appreciated.

Okay, Pablo, I'll address your second question first. The U.S. cannabis industry is indeed very strong and I believe it will continue to be a robust market in terms of revenue and sales. However, we all recognize that until cannabis is legalized at the federal level and banking services are made available to the industry, cash flow will remain a significant challenge. This situation reflects a promising industry with substantial revenue and opportunities. We have been involved in this sector for many years and have experienced the cash flow challenges that all operators face, which directly impacts our business. Consequently, our high level of accounts receivable has been largely driven by these cash flow issues experienced by our customers. So, while there are indeed ongoing opportunities from a revenue perspective, the cash flow challenges for everyone make it difficult for us to achieve our financial goals, at least in the short term, until capital markets open up for the cannabis industry. Legalization is a necessary first step, and we are monitoring developments in that area. When the timing is right, we will consider re-entering the industry. As it stands, we don’t foresee any immediate improvement in cash flow, which is why we decided to pivot. Pablo, could you please remind me of your first question?

Regarding the receivables, I reviewed the financials and noticed a significant provision of approximately $22 million in the fourth quarter. I'm trying to determine whether this amount was related to a single client in one region or if it was a more general precaution, as it appears to be a large provision compared to previous quarters.

Yes. Pablo, yes, that bad debt provision is not based on a few large accounts. It's really quite a cumulative effect of all the customers we did business with in the last 2-plus years after going public. So not a particular customer stands out to answer your question.

Our next question comes from Nick Anderson with ROTH Capital Partners.

First 1 for me is just on the U.K. supply agreement, you're starting to really monetize that deal. I was just wondering if you could maybe share the early feedback from that client and how the agreement is going in terms of order trends? And just going forward, is this the SKU you'll use to shop around to other larger clients? Or are there more additional iterations coming? Thank you.

Nick, this particular ODM client, when we're launching this project now late calendar 2024, we had a version 1 of the product, and correspondingly, as we all know, the U.K. disposable bans affected the dynamics in the e-cig industry in that particular market. Throughout the last 12 months, there have been several significant changes in market trends. As a result of such dynamics, version 1 really didn't take off as the client originally expected. So earlier this year, collectively, we made several changes to their design and upgraded its product significantly. We officially launched it right during the summer this year. Initial feedback is very, very encouraging. To a large degree, in my prepared speech, I mentioned that there was a backlog of $18 million from this space that is largely tied to this particular customer. So merchant tool is truly taking off, and I feel it will meet the original target that the customer set more than a year ago for this product. Of course, I think we are still working on the next iteration, we expect to deliver towards the end of this calendar year. This is such a dynamic industry, a competitive industry. Literally, if you don't introduce new products faster than other brands, it is really, really challenging for the players. So we are trying to make our particular customer very competitive.

Got it. I appreciate that color. Next 1 for me, just on the tariff landscape. You mentioned several larger companies looking to diversify their supply chain. What do you expect just in terms of potentially onboarding some of these larger clients? And has that changed the expansion roadmap for your Malaysian facility?

Okay. Yes, many companies, including brands and manufacturers, have been shifting production outside of China, largely to Southeast Asian countries, so tariff was truly a consideration there. From our point of view, we did see a large number of inbound inquiries from brands and even manufacturing competitors. So we have seen that part. Certainly, we have been preparing for this moment a couple of years back with the selection of Malaysia as our key manufacturing base. As we have been talking about for the last 2 years, our Malaysian operation has been carefully scaled. We wanted to go faster, but we need to obtain regulatory approval; this will take time, so our expansion there is timed by how quickly we get government permits and approvals. On the other hand, with that careful consideration, we built 2 facilities, one small, one large, to address demand that we anticipated a couple of years back regarding geopolitical situations. Right now, we are seriously considering a third facility, which will be much larger in nature to accommodate some potential large ODM projects. It's slow going; of course, we need to be mindful of the regulatory requirements and compliance. But with the presence of such large opportunities, it's important for us to get ahead of the wave of opportunities and have facilities in place before we scale. We are working on building out the production line in the second facility that could house up to 80 e-cigarette production lines. So we are modifying that as the second building. The first building, as we talked about before, had only 6 lines, which were far too small to support such an expanding global e-cigarette ODM business. So the second one comes in handy for us, but still not enough to handle all the opportunities we could potentially entertain.

Got it. Last 1 for me. Just wanted to build off the last cannabis question you answered. I appreciate the color you gave. Rationalization is playing out, and we understand the difficulties in that segment. Would you say the 4Q cannabis revenue number is a more realistic run rate for your U.S. business going forward? Just wondering what that segment could look like this coming year. And just off that, if rescheduling does happen, would it change the way you're looking at U.S. cannabis?

Okay. So yes, cannabis revenue, Q4 is really on the low side. Right now, we are already going at a higher speed in terms of volume. So I would say financial fiscal Q4 2025 is the bottom for our cannabis business, and that largely had to do with as we pivoted. We purposely ended many customer relationships, which had the biggest impact on revenue growth. Q4 reached the very bottom, and we started gaining new customers who will need quality assessment. Plus, we, of course, are continuing with new product development. Before the end of the year, we'd have several new products launched; combined with our high-quality customer base, we think the new products will also bring additional revenue. So your second part of the question regarding rescheduling: Yes, when rescheduling takes place, we would certainly evaluate the opportunity of beefing up investments in the cannabis sector.

Thank you. Ladies and gentlemen, this concludes our question-and-answer session and concludes our call today. We thank you for your interest and participation. You may now disconnect your lines.